Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme

Switch Atlas

Drugs and Medicinal Substances

Hydrochlorothiazide

Cardiovascular System Agents

Hydrochlorothiazide is a small-molecule medicine with the molecular formula C7H8ClN3O4S2 and a molecular weight of about 297.75, recorded in the ChEMBL database as an approved drug whose first approval year is 1959. Its nonproprietary name carries the stem -thiazide, which ChEMBL defines as the thiazide-derivative diuretics. The WHO Anatomical Therapeutic Chemical index files it as C03AA03 among the plain thiazides of the cardiovascular group, and ChEMBL also lists C03AX01 for its combinations. ChEMBL marks it for oral use and lists its approved indications as hypertension, heart failure, nephrotic syndrome, angina pectoris and myocardial infarction. The WHO Model List of Essential Medicines, 24th list (2025), carries it in the core list. This entry records classification and approval facts only and is not medical advice.

Facts
Classification
Approval Status
Approved 1
ATC Class
C: Cardiovascular System 2
Route of Administration
Oral 1
WHO Essential Medicine
Core List 3
First Approved / Isolated Year
1959 1
Connections

Treats

Angina Pectoris, Conditions
Source ChEMBL, EMBL-EBI: Hydrochlorothiazide approved indications (ChEMBL)
Heart Failure, Conditions
Source ChEMBL, EMBL-EBI: Hydrochlorothiazide approved indications (ChEMBL)
Hypertension, Conditions
Source ChEMBL, EMBL-EBI: Hydrochlorothiazide approved indications (ChEMBL)
Myocardial Infarction, Conditions
Source ChEMBL, EMBL-EBI: Hydrochlorothiazide approved indications (ChEMBL)
Nephrotic Syndrome, Conditions
Source ChEMBL, EMBL-EBI: Hydrochlorothiazide approved indications (ChEMBL)
Sources
1. Hydrochlorothiazide (ChEMBL molecule record)
  • ChEMBL molecule record, first_approval
    "first_approval": 1959
  • ChEMBL molecule record, max_phase 4
    "max_phase": "4.0"
  • ChEMBL molecule record, oral flag
    "oral": true
View the Source
2. RxNav RxClass, National Library of Medicine: RxClass ATC classes of Hydrochlorothiazide
RxNav RxClass, National Library of MedicineRxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code C03AA (main group C)
Quote, RxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code C03AA (main group C)
"classId": "C03AA", "className": "Thiazides, plain", "classType": "ATC1-4"
View the Source
3. World Health Organization: The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list
World Health OrganizationPDF page 45; section 12.3; the entry hydrochlorothiazide is in the Core List of the WHO Model List of Essential Medicines, 24th list (2025)
Quote, PDF page 45; section 12.3; the entry hydrochlorothiazide is in the Core List of the WHO Model List of Essential Medicines, 24th list (2025)
hydrochlorothiazide (for indapamide)
View the Source
ChEMBL, EMBL-EBI: Hydrochlorothiazide approved indications (ChEMBL)
ChEMBL, EMBL-EBI
  • Treats: Hypertension, drug_indication record, maximum phase 4, MeSH heading Hypertension
    "max_phase_for_ind": "4.0", "mesh_heading": "Hypertension", "molecule_chembl_id": "CHEMBL435"
  • Treats: Heart Failure, drug_indication record, maximum phase 4, MeSH heading Heart Failure
    "max_phase_for_ind": "4.0", "mesh_heading": "Heart Failure", "molecule_chembl_id": "CHEMBL435"
  • Treats: Nephrotic Syndrome, drug_indication record, maximum phase 4, MeSH heading Nephrotic Syndrome
    "max_phase_for_ind": "4.0", "mesh_heading": "Nephrotic Syndrome", "molecule_chembl_id": "CHEMBL435"
  • Treats: Angina Pectoris, drug_indication record, maximum phase 4, MeSH heading Angina Pectoris
    "max_phase_for_ind": "4.0", "mesh_heading": "Angina Pectoris", "molecule_chembl_id": "CHEMBL435"
  • Treats: Myocardial Infarction, drug_indication record, maximum phase 4, MeSH heading Myocardial Infarction
    "max_phase_for_ind": "4.0", "mesh_heading": "Myocardial Infarction", "molecule_chembl_id": "CHEMBL435"
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.